Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

Navigating human errors in medical device usage: Insights from human factors research

Even the most advanced medical devices can fail patients if used incorrectly. These are the most common errors.

By Samantha Colangelo, M.S. • March 10, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

The top 3 impacts of Trump’s health data purge

Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

By Michael Brady • March 6, 2025

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

Transforming biopharma’s approach to patient engagement with direct-to-patient programs

Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.

By Matthew Walsh, General Manager, Biopharma, ixlayer • March 3, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

In FDA job cuts, experts see threat of far-reaching impact

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025

The kids are alright: How pharma can make inroads with Gen Z

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

By Amy Baxter • Feb. 12, 2025

Are orexins the next golden child of neuroscience?

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

By Meagan Parrish • Feb. 10, 2025

A new, non-opioid pain drug is here. Getting it to patients could be agony.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

By Jacob Bell • Feb. 3, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

By Meagan Parrish • Jan. 24, 2025

Beyond copays: Redefining assistance for those with rare diseases and chronic conditions

 Accessia Health helps ease the burden of managing a rare disease or chronic condition.

Jan. 21, 2025

Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

There’s more to pharma's regulatory story in 2025 than just the IRA.

By Meagan Parrish • Jan. 17, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

Subcutaneous options offer convenience for patients — and a valuable window for drugmakers

New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.

By Kelly Bilodeau • Jan. 7, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024

Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.

By Michael Gibney • Dec. 17, 2024

3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

By Kelly Bilodeau • Dec. 16, 2024

Will the ‘anti-woke’ movement derail DEI efforts in pharma?

Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.

By Meagan Parrish • Dec. 13, 2024

Endometriosis drug research, long underfunded, confronts familiar problems in women’s health

Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.

By Delilah Alvarado • Dec. 11, 2024

How Alexion markets a rare disease drug by ‘starting with the end in mind’

The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.

By Michael Gibney • Dec. 3, 2024

Can the girl power of Arrivo’s depression drug help reverse its fortunes?

After failing a mid-stage trial, the biotech shifted course and is now targeting females with the goal of proving gender can play a role in depression outcomes.

By Kelly Bilodeau • Dec. 3, 2024

Specialized CROs aim to boost participation among women and other underrepresented groups

Lindus Health’s women-focused CRO is the latest in a handful of research efforts to target specialized — and underrepresented — populations.

By Alexandra Pecci • Nov. 27, 2024